<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS199179</article-id><article-id pub-id-type="doi">10.1101/2024.10.01.616022</article-id><article-id pub-id-type="archive">PPR918848</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>mTOR signaling promotes cytokine production in T cells through 3’UTR-mediated translation control</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jurgens</surname><given-names>Anouk P.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Zwijnen</surname><given-names>Josephine</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>van Alphen</surname><given-names>Floris P.J.</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Bradaric</surname><given-names>Antonia</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Rooijers</surname><given-names>Koos</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hoogendijk</surname><given-names>Arie J.</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Popovic</surname><given-names>Branka</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Wolkers</surname><given-names>Monika C.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01fm2fv39</institution-id><institution>Sanquin Blood Supply Foundation</institution></institution-wrap>, Department of Research, T cell differentiation lab, <addr-line>Plesmanlaan 125</addr-line>, <postal-code>1066 CX</postal-code><city>Amsterdam</city>, <country country="NL">The Netherlands</country>, and</aff><aff id="A2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01fm2fv39</institution-id><institution>Sanquin Blood Supply Foundation</institution></institution-wrap>, Department of Research, Bleeding &amp; Hemostasis, <addr-line>Plesmanlaan 125</addr-line>, <city>Amsterdam</city>, <country country="NL">The Netherlands</country>, and</aff><aff id="A3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05grdyy37</institution-id><institution>Amsterdam UMC</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04dkp9463</institution-id><institution>University of Amsterdam</institution></institution-wrap>, Landsteiner Laboratory, <addr-line>Meibergdreef 9</addr-line>, <postal-code>1105 AZ</postal-code><city>Amsterdam</city>, <country country="NL">The Netherlands</country>, and Amsterdam Institute for Infection &amp; Immunity, and Cancer Center Amsterdam - Cancer Immunology, Amsterdam, The Netherlands</aff><aff id="A4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01n92vv28</institution-id><institution>Oncode Institute</institution></institution-wrap>, <city>Utrecht</city>, The <country country="NL">Netherlands</country></aff><author-notes><corresp id="CR1">
<label>*</label>Corresponding author <email>m.wolkers@sanquin.nl</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>04</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="preprint"><day>02</day><month>10</month><year>2024</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">T cells are key contributors to clear our body from infected and malignant cells. When T cells respond to target cells, they undergo profound translational alterations. The evolutionary and highly conserved kinase mammalian target of rapamycin (mTOR) is a central mediator of T cell differentiation, homeostasis, and T cell activation, including the production of the key pro-inflammatory cytokines TNF, IL2, and IFNγ. mTOR was shown to execute its translation activity through TOP motifs located in the 5’ Untranslated region (5’UTR) of its target genes. Here, we uncovered a distinct mechanism of mTOR signaling on cytokine production in T cells, which is under control of the 3’UTR. Even though non-classical TOP motifs are present in cytokine 3’UTRs, they do not contribute to mTOR-mediated translation regulation. Rather, AU-rich elements (AREs) are required for mTOR-mediated cytokine production. Furthermore, we discovered that the RNA binding protein DDX21 binds to 3’UTR AREs and confers the mTOR-mediated translation control. In conclusion, we here present a previously unappreciated ARE-dependent, 3’UTR-mediated mode of action that mTOR employs to regulate cytokine production.</p></abstract><kwd-group><kwd>T cell</kwd><kwd>post-transcriptional regulation</kwd><kwd>RNA-binding protein (RBP)</kwd><kwd>mammalian target of rapamycin (mTOR)</kwd><kwd>3’Untranslated region (UTR)</kwd><kwd>ARE-binding protein</kwd><kwd>cytokine regulation</kwd><kwd>DDX21</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">T cells constitute a critical component of the adaptive immune system against pathogens and cancer cells. To perform their function effectively, T cells require precise control of protein expression, which is in particular important during T cell activation, when they produce key effector molecules such as pro-inflammatory cytokines <sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref></sup>. mTOR is one of the key regulators of T cell biology, as its signaling promotes T cell growth, proliferation and effector function, and regulates T cell fate decisions <sup><xref ref-type="bibr" rid="R3">3</xref>–<xref ref-type="bibr" rid="R9">9</xref></sup>. Likewise, mTOR signaling regulates the rate of protein translation by integrating the signals a T cell receives through the T cell receptor (TCR), co-stimulatory receptors, and cytokine receptors <sup><xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R10">10</xref>–<xref ref-type="bibr" rid="R13">13</xref></sup>. mTOR-signaling also coordinates the fine-tuning of gene expression <sup><xref ref-type="bibr" rid="R5">5</xref></sup>. For instance, mTORC1 regulates the cytotoxicity in murine T cells, and its inhibition hampers the expression of various effector molecules such as IFNγ <sup><xref ref-type="bibr" rid="R6">6</xref></sup>. However, how mTOR signaling acts on its target mRNAs, and how it promotes cytokine expression in T cells is, to date not fully understood.</p><p id="P3">In addition to the coding sequence, sequences within the untranslated regions (UTRs) of the mRNA, i.e. the 5’UTR and 3’UTR, are key contributors to translation control. In particular RNA-binding proteins (RBPs) convey the regulation of - amongst other processes - RNA splicing, poly-adenylation, localization, stability and translation of (m)RNA <sup><xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R14">14</xref>–<xref ref-type="bibr" rid="R19">19</xref></sup>. mTOR-mediated regulation of translation can also be mediated by RBPs: mTOR phosphorylates the translation inhibitor LARP, resulting in its dissociation from cytidine and pyrimidine-rich 5’terminal oligopyrimidine (TOP)-like motifs in the 5’UTR of its target mRNAs <sup><xref ref-type="bibr" rid="R20">20</xref>–<xref ref-type="bibr" rid="R22">22</xref></sup>. The release of LARP from its target mRNA, along with the mTOR mediated phosphorylation of the translation inhibitor 4E-BP allows the eukaryotic initiation factors (eIFs) to engage with the 5’UTR and to initiate translation <sup><xref ref-type="bibr" rid="R23">23</xref></sup>. However, also the 3’UTR can contribute to translation control <sup><xref ref-type="bibr" rid="R18">18</xref></sup>, and mTOR signaling could possibly contribute to this regulation. In mouse embryonic fibroblasts, mTOR signaling was reported to modulate translation by 3’UTR shortening, which led to increased polysome association and translation of its target genes <sup><xref ref-type="bibr" rid="R24">24</xref></sup>. Whether mTOR signaling can also directly contribute to the 3’UTR-mediated translation control in T cells has not been studied yet is conceivable provided its key role in regulating protein expression.</p><p id="P4">In this study, we uncovered that mTOR signaling coordinates the translation of the three key pro-inflammatory cytokines TNF, IL2 and IFNγ in human T cells through their 3’UTR. Surprisingly, we found that the non-classical TOP-like motifs present in all three cytokine 3’UTRs are redundant. Rather, AU-rich elements (ARE) are required for the mTOR-mediated translation control. With RBP-pulldown assays, we identified several RBPs that engage with AREs in the IL2 3’UTR in an mTOR-dependent manner. Specifically, DDX21 is required for the IL2 3’UTR specific regulatory function of mTOR. Combined, we reveal that mTOR-mediated regulation of ARE binding proteins to 3’UTRs of target mRNAs supports the protein production upon T cell activation.</p></sec><sec id="S2" sec-type="results"><title>Results</title><sec id="S3"><title>mTOR negatively influences cytokine production in human T cells</title><p id="P5">To study the mTOR-mediated regulation of cytokine production in effector CD3<sup>+</sup> T cells (Teff), <italic>we</italic> activated human peripheral blood-derived T cells for 48h with αCD3/αCD28, which were then rested for 96h. When reactivated with phorbol myristate acetate (PMA)/ionomycin, T cells display similar rapid cytokine production kinetics as <italic>ex vivo</italic> activated Teff and memory T cells <sup><xref ref-type="bibr" rid="R25">25</xref>–<xref ref-type="bibr" rid="R27">27</xref></sup>. Blocking mTOR during T cell activation with the ATP-competitive mTORC1/mTORC2 inhibitor Torin-1 (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 1A</xref>) <sup><xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R29">29</xref></sup>, or with the mTORC1 selective, allosteric, inhibitor Rapamycin <sup><xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R29">29</xref></sup> did not affect cell viability, nor the induction of the early T cell activation marker CD69 when compared to DMSO control-treated T cells (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 1 B,C</xref>). Yet, and as previously reported for murine T cells <sup><xref ref-type="bibr" rid="R6">6</xref></sup>, mTOR inhibition by Torin-1 significantly decreased the production and secretion of TNF and IL2 and showed a trend for IFNγ in human T cells (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 1D, E</xref>). Similar effects were observed on cytokine production upon Rapamycin treatment (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 1F</xref>), indicating that the cytokine production in T cells is primarily regulated through mTORC1. Notably, whereas mTOR inhibition affected the cytokine production, effects on cytokine mRNA levels and RNA stability were limited (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 1G</xref>). Thus, mTOR signaling promotes protein production of pro-inflammatory cytokines in human T cells, and it does so through translation control.</p></sec><sec id="S4"><title>mTOR-mediated regulation of protein expression employs cytokine 3’UTRs</title><p id="P6">Next, we questioned how mTOR regulates the production of cytokines in human CD8<sup>+</sup> T cells. We and others previously reported the importance of cytokine 3’UTRs in fine-tuning protein production <sup><xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R16">16</xref>–<xref ref-type="bibr" rid="R18">18</xref>,<xref ref-type="bibr" rid="R30">30</xref>,<xref ref-type="bibr" rid="R31">31</xref></sup>. This became particularly evident with full length <italic>TNF</italic>, <italic>IL2,</italic> or <italic>IFNG</italic> 3’UTR GFP reporter constructs that substantially increased their protein expression upon T cell activation<sup><xref ref-type="bibr" rid="R31">31</xref></sup>. Whether mTOR signaling contributes to the 3’UTR-mediated protein regulation in T cells, has however not yet been studied. To test this, we measured the effect of Torin-1 treatment on <italic>TNF</italic>, <italic>IL2,</italic> or <italic>IFNG</italic> 3’UTR GFP reporter constructs. <italic>GZMB</italic> 3’UTR that lacks regulatory capacities in activated T cells<sup><xref ref-type="bibr" rid="R31">31</xref></sup> and GFP fused to no 3’UTR (GFP-control) served as control.</p><p id="P7">Torin-1 treatment did not affect GFP reporter expression in resting T cells (<xref ref-type="fig" rid="F1">Figure 1A</xref> &amp; <xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 2A</xref>). Likewise, when Teff cells carrying GFP-control or GFP-<italic>GZMB</italic> 3’UTR were activated with PMA/Ionomycin, only mild effects on GFP protein expression levels were observed when mTOR signaling was blocked (<xref ref-type="fig" rid="F1">Figure 1A</xref> &amp; <xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 2A</xref>). In sharp contrast, the induction of GFP protein expression under control of the three cytokine 3’UTRs was substantially impaired when mTOR was blocked with Torin-1 or Rapamycin, a feature that was most prominent for the <italic>IL2</italic> and <italic>IFNG</italic> 3’UTR (<xref ref-type="fig" rid="F1">Figure 1A</xref> &amp; <xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 2B</xref>). Similar results were obtained upon αCD3/αCD28 stimulation (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 2C</xref>). Of note, this mTOR-sensitive, 3’UTR-mediated regulation of protein expression was conserved in human CD4<sup>+</sup> T cells (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 2D</xref>). In conclusion, mTOR signals through cytokine 3’UTRs to promote protein production in T cells.</p></sec><sec id="S5"><title>TOP-like motifs in the 3’UTR do not contribute to mTOR mediated protein production</title><p id="P8">We then sought to define which motifs in the cytokine 3’UTRs mediate the mTOR-driven regulation. mTOR signaling can phosphorylate the translation inhibitor LARP1, which then dissociates from CTTT-rich TOP-like motifs in the 5’UTR of its target genes <sup><xref ref-type="bibr" rid="R21">21</xref>,<xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R32">32</xref></sup>. Interestingly, LARP1 was recently shown to interact with 3’UTRs in HEK293T cells <sup><xref ref-type="bibr" rid="R21">21</xref></sup>. Therefore, we searched for TOP-like CTTT motifs in the cytokine 3’UTRs, and we found them present in all three cytokine 3’UTRs (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 2E</xref>). To test whether the TOP-like motifs were sensitive to mTOR signaling, we mutated the CTTT motifs into CGTT in the full length 3’UTRs (<xref ref-type="fig" rid="F1">Figure 1B</xref>). Surprisingly, these mutants were equally responsive to Torin-1 as the WT cytokine 3’UTRs (<xref ref-type="fig" rid="F1">Figure 1B</xref>), indicating that TOP-like CTTT motifs in the 3’UTRs did not contribute to mTOR-mediated protein expression. When re-examining the cytokine 3’UTRs, we observed that the CTTT motifs clustered together (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 2E</xref>). We therefore generated CTTT-rich and CTTT-poor fragments for each cytokine 3’UTR to identify the Torin-1 sensitive fragment. Again, GFP reporters containing the CTTT-rich fragments poorly responded to Torin-1 treatment (<xref ref-type="fig" rid="F1">Figure 1C-E</xref>). Conversely, the CTTT-poor fragments of all three cytokine 3’UTRs were sensitive to Torin-1 treatment and displayed significantly reduced protein expression upon T cell activation (<xref ref-type="fig" rid="F1">Figure 1C-E</xref>). In conclusion, TOP-like CTTT motifs in cytokine 3’UTRs do not contribute to mTOR-mediated regulation of protein production.</p></sec><sec id="S6"><title>mTOR regulates 3’UTR-mediated protein expression through AU-rich elements</title><p id="P9">To uncover which motifs in the cytokine 3’UTRs were responsive to mTOR signaling, we zoomed in on the Torin-1 sensitive 3’UTR fragments. The CTTT-poor regions of all three cytokine 3’UTRs contained AU-rich elements (AREs), sequences that were identified as key hubs for RBPs for regulating cytokine expression (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 2E</xref>) <sup><xref ref-type="bibr" rid="R15">15</xref>,<xref ref-type="bibr" rid="R17">17</xref>,<xref ref-type="bibr" rid="R18">18</xref>,<xref ref-type="bibr" rid="R33">33</xref>–<xref ref-type="bibr" rid="R35">35</xref></sup>. To study the contribution of AREs to the mTOR-mediated regulation of protein expression, we mutated the AREs, defined here as TATTTA, to TATGTA in the full-length cytokine 3’UTRs (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 2E</xref>). Strikingly, at all time points measured, mutating AREs in the cytokine 3’UTRs substantially reduced the effect of mTOR inhibition on protein expression (<xref ref-type="fig" rid="F2">Figure 2A-C</xref>). The effect of ARE mutations on protein expression was detected for all cytokine 3’UTRs but was most prominent for the <italic>IL2</italic> and <italic>IFNG</italic> 3’UTRs (<xref ref-type="fig" rid="F2">Figure 2A-C</xref>). Thus, ARE sequences in cytokine 3’UTRs mediate the mTOR signaling effects on protein production.</p></sec><sec id="S7"><title>Identification of mTOR-mediated RBP binding to AREs in the IL2 3’UTR</title><p id="P10">Having established that AREs within cytokine 3’UTRs were required for mTOR-mediated protein production, we next aimed to identify which RBP drives this regulation. As a representative example, focused on the <italic>IL2</italic> 3’UTR, and we performed an RNA aptamer pulldown <sup><xref ref-type="bibr" rid="R31">31</xref>,<xref ref-type="bibr" rid="R36">36</xref></sup>. We first generated <italic>in vitro</italic> transcribed RNA with streptavidin binding 4xS1 RNA aptamers containing the full-length <italic>IL2</italic> WT 3’UTR, or the <italic>IL2</italic> ARE-mut 3’UTR as bait (<xref ref-type="fig" rid="F3">Figure 3A</xref>). The aptamers were then exposed to cell lysates from <italic>in vitro</italic> generated human CD3<sup>+</sup> T cells that were activated for 3h with αCD3/αCD28 in the presence or absence of Torin-1. With this approach we could 1) measure RBP binding in the context of the full T cell proteome, 2) define ARE-dependent interactions upon T cell activation, and 3) study the effects of mTOR inhibition on RBP interactions with the target mRNA.</p><p id="P11">Mass spectrometry analysis of the RNA aptamer pulldown with streptavidin beads detected in total 693 proteins (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 3A-D</xref> &amp; <xref ref-type="supplementary-material" rid="SD2">Supplemental table 1</xref>). To identify ARE-binding proteins (ARE-BPs), we focused on proteins that showed enriched binding to the <italic>IL2</italic> WT 3’UTR compared to the <italic>IL2</italic> ARE-mut 3’UTR (<xref ref-type="fig" rid="F3">Figure 3B</xref>). As expected, we identified the canonical ARE-BPs ZFP36, ZFP36L1 and ZFP36L2 (<xref ref-type="fig" rid="F3">Figure 3B</xref>), which all depend on AREs for their interaction (<xref ref-type="fig" rid="F3">Figure 3C</xref>). Other previously undescribed ARE interactors included DDX17, DDX5 and THUMPD1 (<xref ref-type="fig" rid="F3">Figure 3B, C</xref> &amp; <xref ref-type="supplementary-material" rid="SD3">Supplemental table 2</xref>). To identify ARE-BPs that respond to mTOR signaling, we used supervised classification (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 4E</xref>) <sup><xref ref-type="bibr" rid="R38">38</xref></sup>. We ordered ARE-BPs with reduced (‘Torin-1 repelled’) or increased (‘Torin-1 induced’) interaction with AREs upon Torin-1 treatment (LFC&gt;1, p&lt;0.05). We found 13 proteins that interacted with AREs in a Torin-1 dependent manner (<xref ref-type="fig" rid="F3">Figure 3D</xref> &amp; <xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 3D</xref>). Notably, this did not include ZFP36, ZFP36L1, and ZFP36L2, whose interaction to AREs was insensitive to Torin-1 treatment (<xref ref-type="fig" rid="F3">Figure 3C</xref> &amp; <xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 3D, E</xref>). 6 of the 13 Torin-1 sensitive ARE-BPs (TCP1, LSM7, PRMT1, DDX21, RPL14 and RPL7) displayed reduced interaction, and 7 proteins (COX6A1, RRBP1, TMSB15A/B, FKBP3, PKM, EDF1, ENO1) displayed increased interaction with AREs upon mTOR inhibition (<xref ref-type="fig" rid="F3">Figure 3D, E</xref> top). Of note, none of the observed changes in binding of AREs upon Torin-1 treatment could not be attributed to overall changes in protein expression, which remained unaltered (<xref ref-type="fig" rid="F3">Figure 3E</xref>, bottom). In conclusion, we show here that - in addition to the classical (mTOR-insensitive) ARE-BPs - RBPs can depend on mTOR signaling for their interaction to AREs.</p></sec><sec id="S8"><title>mTOR regulates IL2 cytokine expression through the 3’UTR-binding protein DDX21</title><p id="P12">We followed up on 5 proteins that we identified as mTOR-sensitive ARE-BPs, and that displayed increased (EDF1) or decreased (TCP1, PRMT1, LSM7, and DDX21) interaction with the <italic>IL2</italic> 3’UTR upon Torin-1 treatment (<xref ref-type="fig" rid="F3">Figure 3D, E</xref>). Upon successful CRISPR-Cas9 gene-editing (<xref ref-type="fig" rid="F4">Figure 4A</xref>), all RBP deficient CD3<sup>+</sup> T cells – except for EDF1 – had lower cell viability and lower cell count compared to non-targeting CRISPR RNA control, highlighting their relevance for T cell fitness (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 4A, B</xref>). Most strongly affected were LSM7 KO T cells and TCP1 KO T cells, the latter as reported for murine T cells <sup><xref ref-type="bibr" rid="R39">39</xref></sup>.</p><p id="P13">In non-activated ARE-BP deficient T cells, GFP protein expression were comparable to that of control T cells. Also Torin-1 treatment had no noticeable effects on protein expression in resting T cells. Upon T cell activation, however, only EDF1 KO T cells maintained similar GFP expression levels as the control (<xref ref-type="fig" rid="F4">Figure 4B</xref>). Deletion of all other ARE-BP candidates resulted in 30-35% reduction of the GFP gMFI expression compared to control treated T cells, indicating that TCP1, LSM7, PRMT1 and DDX21 regulate protein expression through the <italic>IL2</italic> 3’UTR (<xref ref-type="fig" rid="F4">Figure 4B</xref>). Of note, all RBP-KO cells reached similar induction levels of the activation marker CD69, indicating that not all features of T cell activation were affected (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 4C</xref>).</p><p id="P14">We then tested the effect mTOR inhibition on activated ARE-BP KO T cells. EDF1 KO and LSM7 KO T cells maintained their sensitivity to Torin-1 treatment, which was also observed to some extent for PRMT1 KO T cells (<xref ref-type="fig" rid="F4">Figure 4C</xref>). In contrast, TCP1 KO and DDX21 KO T cells almost completely lost the sensitivity to Torin-1 treatment (<xref ref-type="fig" rid="F4">Figure 4C, D</xref>). Because TCP1 deficiency substantially affected cell viability and expansion (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 4A, B</xref>), we focused our studies on DDX21.</p><p id="P15">Measuring protein expression levels over time revealed that DDX21 KO T cells phenocopied the GFP expression levels of Torin-1 treated control T cells (<xref ref-type="fig" rid="F4">Figure 4E</xref>), indicating that DDX21 is a prominent contributor to the mTOR-mediated, <italic>IL2</italic> 3’UTR-driven protein production. Furthermore, DDX21 deficient cells phenocopied the protein expression levels of <italic>IL2</italic> 3’UTR ARE mutants, and DDX21 KO T cells did not further alter protein expression in the presence of the <italic>IL2</italic> 3’UTR ARE mutant (<xref ref-type="fig" rid="F4">Figure 4F</xref>), providing additional evidence that the prime activity of DDX21 on GFP protein expression is through AREs in the <italic>IL2</italic> 3’UTR.</p><p id="P16">To study if DDX21 is phosphorylated downstream of mTOR signaling, we mined phospho-proteomics data of activated Jurkat cells <sup><xref ref-type="bibr" rid="R40">40</xref></sup> and mouse T cells <sup><xref ref-type="bibr" rid="R10">10</xref></sup>. Both studies identified several species-specific and conserved activation-induced serine/threonine phosphorylation sites in DDX21 (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 4D</xref>). Notably, some phosphorylation sites were lost in T cells from Raptor KO mice (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 4D</xref>), further indicating that phosphorylation of DDX21 is downstream of mTOR signaling.</p><p id="P17">Finally, to determine whether DDX21 could be involved also in the observed mTOR-mediated regulation of TNF and IFNγ protein production, we examined its binding to the <italic>TNF</italic> 3’UTR and the <italic>IFNG</italic> 3’UTR. Using our previously published aptamer-pulldown data with the three cytokine 3’UTRs from activated T cells<sup><xref ref-type="bibr" rid="R31">31</xref></sup> we found that DDX21 displayed significantly increased interaction for the <italic>TNF</italic> 3’UTR and <italic>IL2</italic> 3’UTR when compared to the empty aptamer control, and a trend for increased interaction with the <italic>IFNG</italic> 3’UTR (<xref ref-type="fig" rid="F4">Figure 4G</xref>). Thus, the observed mTOR-mediated interaction of the novel ARE-BP DDX21 to 3’UTRs is observed upon T cell activation for all three measured cytokines.</p></sec></sec><sec id="S9" sec-type="discussion"><title>Discussion</title><p id="P18">The interplay between mTOR signaling and cytokine regulation represents a crucial nexus for controlling immune responses. mTOR impacts the availability and activity of translation initiation factors, nutrients and ribosomal proteins <sup><xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R41">41</xref></sup>. In addition, mTOR signaling can regulate mRNA stability and translation rate, by modulating the binding of LARP to the 5’UTR of its target mRNAs <sup><xref ref-type="bibr" rid="R20">20</xref>–<xref ref-type="bibr" rid="R22">22</xref>,<xref ref-type="bibr" rid="R42">42</xref>–<xref ref-type="bibr" rid="R44">44</xref></sup>. Here, we uncovered a previously uncharacterized 3’UTR-mediated mechanism that mTOR employs to promote cytokine production upon T cell activation: mTOR signaling promotes binding of DDX21 to AREs in the cytokine 3’UTRs, which in turn supports the cytokine production. To our knowledge, this is the first report that reveals a link between T cell activation-induced mTOR signaling and ARE dependent 3’UTR-mediated control of protein production.</p><p id="P19">We here identified mTOR-sensitive and mTOR-insensitive ARE-BPs. The prototypic ARE-BPs such as ZFP36 family members were mTOR-insensitive. ARE-BPs that were mTOR sensitive included DDX21. Intriguingly, the mTOR-mediated interaction of DDX21 with AREs measurable already at 2-3h upon T cell activation promotes protein expression. In contrast, ZFP36 family members dampen cytokine production by promoting RNA degradation <sup><xref ref-type="bibr" rid="R47">47</xref></sup>.</p><p id="P20">However, they do so by interacting with AREs at later time points, i.e. from 4h onwards of T cell activation <sup><xref ref-type="bibr" rid="R31">31</xref>,<xref ref-type="bibr" rid="R48">48</xref>,<xref ref-type="bibr" rid="R49">49</xref></sup>. Thus, AREs appear to be prime hubs for fine-tuning the regulation of cytokine production. It is yet to be determined whether the replacement of DDX21 by ZFP36 proteins is passive, dictated by loss of phosphorylation of DDX21, or whether ZFP36 family members have a higher abundance or an affinity for AREs, and thus outcompete DDX21 for binding to AREs. Irrespective of the underlying mechanism, we show here that mTOR mediated regulation of DDX21 binding supports the rapid cytokine production upon T cell activation, a feature that is critical to dampen viral spread.</p><p id="P21">Not all three cytokine 3’UTRs respond equally strongly to Torin-1 treatment. This different sensitivity could possibly stem from the location of the ARE motifs within the 3’UTR. In the <italic>IFNG</italic> 3’UTR, AREs are located at the 5’end, in the <italic>TNF</italic> 3’UTR at the 3’end, and in the <italic>IL2</italic> 3’UTR at both ends. Provided that 3’UTRs can be shortened upon T cell activation <sup><xref ref-type="bibr" rid="R24">24</xref>,<xref ref-type="bibr" rid="R50">50</xref>,<xref ref-type="bibr" rid="R51">51</xref></sup>, alternative 3’UTR splicing could possibly remove AREs when located at the 3’end. Therefore, TNF may depend less on ARE-mediated regulation and more on other regulatory features, such as stem-loop -mediated regulation <sup><xref ref-type="bibr" rid="R36">36</xref></sup>. Furthermore, we recently reported that the relative contribution to protein abundance of sequence features such as CTTT and ARE motifs strongly depends on their location, occurrence and spacing in the mRNA, and this relation holds true for 3’UTRs <sup><xref ref-type="bibr" rid="R52">52</xref></sup>. Therefore, it is tempting to speculate that the sequence context of AREs in the three cytokine 3’UTRs (and potentially that of other ARE-containing 3’UTRs) determines the sensitivity to mTOR signaling.</p><p id="P22">mTOR is considered a key regulator of translation. However, due to low expression levels of the inhibitory protein 4E-BP in human T cells, which results in a stoichiometry between 4E-BP and eIF4E of 3-8:1, it is postulated that only a subset of eIF4E-sensitive transcripts, including proinflammatory effector molecules, are responsive to 4E-BP in T cells and consequently to mTOR regulation <sup><xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R53">53</xref>,<xref ref-type="bibr" rid="R54">54</xref></sup>. We found here that cytokine 3’UTRs can substantially contribute to the mTOR-mediated protein production upon T cell activation. This was not the case for <italic>GZMB</italic> 3’UTR, possibly because the human <italic>GZMB</italic> 3’UTR contains only one ARE motif.</p><p id="P23">In conclusion, we present a novel mechanism that mTOR employs to control protein production. Our results reveal the effects of mTOR signaling on determining RBP binding to AREs within the 3’UTR and, consequently, on mRNA processing and translation. The ARE-mediated effects of mTOR signaling thus contribute to the regulation of pro-inflammatory cytokine production, which is crucial for coordinating and regulating T cell responses in health and disease.</p><sec id="S10"><title>Resource Availability</title><p id="P24">Lead contact Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Monika C. Wolkers (<email>m.wolkers@sanquin.nl</email>).</p></sec><sec id="S11"><title>Materials Availability</title><p id="P25">This study did not generate new unique reagents.</p></sec></sec><sec id="S12" sec-type="methods"><title>Methods</title><sec id="S13"><title>Cell culture</title><p id="P26">Peripheral blood mononuclear cells (PBMCs) from anonymized healthy donors were used in accordance with the Declaration of Helsinki (Seventh Revision, 2013) after written informed consent (Sanquin). PBMCs were isolated through Lymphoprep density gradient separation (Stemcell Technologies). Cells were used after cryopreservation. T cells were activated for 48h as described previously <sup><xref ref-type="bibr" rid="R56">56</xref></sup>. Briefly, 24-well plates were pre-coated overnight at 4°C with 4μg/mL rat a-mouse IgG2a (MW1483, Sanquin) in phosphate-buffered saline (PBS). Plates were washed with PBS and coated for &gt;3 h with 1 μg/mL αCD3 (HIT3a, Biolegend) at 37°C. 1.3x10<sup>6</sup> PBMCs/well were seeded with 1 μg/mL soluble αCD28 (CD28.2, Biolegend) in 1 mL Iscove’s Modified Dubecco’s Medium (IMDM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mM L-glutamine. After 48h of activation at 37°C, 5% CO2, cells were harvested and cultured in standing T25/T75 tissue culture flasks (Thermo Scientific) at a density of 0.8x10<sup>6</sup>/mL in IMDM supplemented with 10% FBS and 100 IU/mL recombinant human rhIL2 (Protech) and 10 ng/mL rhIL-15 (Protech). Medium was refreshed every 2-3 days. Upon nucleofection, T cells were cultured in T cell mixed media (Miltenyi) supplemented with 5% heat-inactivated human serum, 5% FBS, 100 U/mL Penicillin, 100 mg/mL streptomycin, 2 mM L-glutamine, 100 IU/mL rhIL-2 (Peprotech), and 10 ng/mL rhIL-15 (Peprotech). Human fibrosarcoma FLYRD18 cells (FLYRD18) were cultured in IMDM supplemented with 10% FBS, 1% L-glutamine, 1% Penicillin-Streptomycin antibiotic solution at 37°C, 5% CO2 and split every 2 days at 1:10.</p></sec><sec id="S14"><title>Generation of GFP reporter constructs</title><p id="P27">GFP constructs with full length cytokine 3’UTRs were reported before <sup><xref ref-type="bibr" rid="R31">31</xref></sup>. Cytokine 3’UTR fragments and full length 3’UTRs containing CTTT--&gt; CGTT or AUUUA--&gt; AUGUA point mutants containing BamHI and NotI restriction sites were obtained as minigenes from IDT and inserted into pRS_PGK_GFP according to manufacturer’s protocol (T4; NEB). Plasmid DNA was amplified in DH5alpha super-competent bacteria (NEB) and isolated with NucleoSpin Plasmid Transfection-grade Mini-Prep isolation kit (Machery-Nagel). 3’UTR sequences were confirmed with Sanger sequencing.</p></sec><sec id="S15"><title>Virus production and retroviral transduction</title><p id="P28">1x10<sup><xref ref-type="bibr" rid="R5">5</xref></sup> FLYRD18 cells per 6-well culture plates were pre-seeded and cultured overnight at 37°C. Transfection with GFP reporter constructs was carried out with GeneJammer (Agilent) according to the manufacturer’s protocol and incubated overnight at 32°C. T cells activated for 48h were retrovirally transduced with Retronectin (Takara) as previously described <sup><xref ref-type="bibr" rid="R31">31</xref></sup>. Briefly, non-tissue cultured treated 24-well plates were pre-coated overnight with 50 μg/mL Retronectin (Takara) and washed once with PBS. 800 μL viral supernatant/well was added and spun at 4°C at 2820g. 1x10<sup>6</sup> T cells/well were added, plates spun for 5 min at 180g and incubated overnight at 37°C. Supernatant was replaced with fresh culture medium. After 48h, T cells were harvested and cultured in T25/T75 flasks for 6–8 days as described above.</p></sec><sec id="S16"><title>T cell activation and flow cytometric measurement of protein expression</title><p id="P29">T cells were activated in culture medium in 96-wells plates with 10 ng/mL Phorbol Myristate Acetate (PMA) and 1μM lonomycin, or with αCD3 (Pelicluster; Sanquin) and αCD28 (Biolegend), 1μg/mL each. To block mTOR, 250nM Torin-1, or 10nM Rapamycin or dissolvent DMSO (0.05% for Torin-1, 0.01% for Rapamycin) was added during stimulation. Non-stimulated T cells treated with mTOR inhibitors and/or DMSO control for 12h were included as controls.</p><p id="P30">To analyze GFP protein expression, T cells were washed with FACS buffer (PBS, containing 1% FBS and 2 mM EDTA) and labeled for 20 min at 4°C with indicated antibodies (see <xref ref-type="supplementary-material" rid="SD5">Appendix A</xref>). Dead cells were excluded with Near-IR (Life Technologies). For intracellular cytokine staining, cells were cultured with 1 μg/mL brefeldin A for indicated time points, fixed, and permeabilized with Cytofix/Cytoperm kit according to the manufacturer’s protocol (BD Biosciences) prior to acquisition using FACSymphony. Data were analyzed with FlowJo (BD Biosciences, version 10).</p></sec><sec id="S17"><title>FluoroSpot Cytokine Assay</title><p id="P31">Fluorospot cytokine assay was performed at day 4 after T cell activation according to the manufacturer’s instructions (Mabtech). Briefly, 1x10<sup>4</sup> CD3<sup>+</sup> T cells/well were plated in pre-coated IFNγ/IL2/TNF Fluorospot plates (Mabtech) and cultured overnight in medium alone (negative control) or were activated with αCD3/αCD28 (supplied by kit), in the presence of 250nM Torin-1 or DSMO control 12h. Fluorospot plates were developed and evaluated using the ImmunoSpot S6 Ultra-V (CTL) with the accessory software.</p></sec><sec id="S18"><title>Quantitative PCR analysis</title><p id="P32">Total RNA was extracted using Quick-RNA MiniPrep plus kip (Zymo). T cells were activated in triplicate for indicated 3h with αCD3/αCD28. For mRNA half-life measurements, cells were treated for an additional 1h or 2h with 5 μg/mL actinomycin D (ActD) (Sigma-Aldrich). cDNA was synthesized with SuperScript III (Invitrogen), RT-PCR was performed using SYBR Green on a StepOne Plus (Applied Biosystems). Ct values were normalized to 18S levels.</p></sec><sec id="S19"><title>Generation of in vitro transcribed S1m aptamers containing the <italic>IL2</italic> 3’UTR</title><p id="P33">Full-length 3’UTRs were ordered as gBlocks from IDT and cloned into BamHI and NotI sites of pRETRO-SUPER-GFP downstream of GFP <sup><xref ref-type="bibr" rid="R31">31</xref></sup>. 4xS1m RNA aptamers containing the full-length human WT <italic>IL2</italic> 3’UTR or ARE-mut <italic>IL2 3</italic>’UTR were cloned into the pSP73-flip-4xS1m vector, linearized with NdeI, and <italic>in vitro</italic> transcribed with AmpliScribe T7 flash transcription kit (Epicentre) as previously described <sup><xref ref-type="bibr" rid="R18">18</xref>,<xref ref-type="bibr" rid="R31">31</xref></sup>. RNA quality and quantity was determined by RNAnano Chip assay (Agilent).</p></sec><sec id="S20"><title>4xS1m RNA aptamer-protein pull-down</title><p id="P34">CD3<sup>+</sup> T cells were activated for 48h with αCD3/αCD28 and rested for 5 days in the presence of 100 IU/mL rhIL2 as described above. T cells were left untreated or reactivated for 3h with αCD3/αCD28 in the presence of Torin-1 or DMSO. Cells were pelleted and washed twice with ice-cold PBS. Cell pellet was snap frozen in liquid nitrogen, homogenized using 5-mm steel beads and a tissue lyser (Qiagen TissueLyser II) 6x at 25 Hz for 15s. The homogenate was solubilized and precleared with Avidin agarose beads (Thermo Scientific) for 30 min at 4°C and with Streptavidin Sepharose High Performance beads (GE Healthcare) for 2h at 4°C. Cell lysates were incubated with RNA-aptamer-coupled beads for 3.5h at 4°C under rotation in the presence of 60 U RNasin (Ambion). For each pull-down, 30 μg of in vitro transcribed RNA, coupled to Streptavidin Sepharose beads, and 5–10mg cell lysate protein was used. RNA-bound proteins were eluted by adding 1 μg RNaseA (Thermo Scientific) in 100mL 100mM Tris-HCl, pH 7.5 (Gibco-Invitrogen). Proteins were reduced, alkylated, and digested into peptides using trypsin (Promega). Peptides were desalted and concentrated using Empore-C18 StageTips and eluted with 0.5% (v/v) acetic acid, 80% (v/v) acetonitrile. Sample volume was reduced by SpeedVac and supplemented with 2% acetonitrile and 0.1% TFA.</p></sec><sec id="S21"><title>Mass spectrometry data acquisition</title><p id="P35">Tryptic peptides were separated by nanoscale C18 reverse phase chromatography coupled online to an Orbitrap Fusion Lumos Tribrid mass spectrometer (Thermo Scientific) via a nanoelectrospray ion source (Nanospray Flex Ion Source, Thermo Scientific). Peptides were loaded on a 20cm 75-360μm inner-outer diameter fused silica emitter (New Objective) packed in-house with ReproSil-Pur C18-AQ, 1.9μm resin (Dr Maisch GmbH). The column was installed on a Dionex Ultimate3000 RSLC nanoSystem (Thermo Scientific) using a MicroTee union formatted for 360μm outer diameter columns (IDEX) and a liquid junction. The spray voltage was set to 2.15kV. Buffer A was composed of 0.1% formic acid and buffer B of 0.1% formic acid, 80% acetonitrile. Peptides were loaded for 17 min at 300nl/min at 5% buffer B, equilibrated for 5 min at 5% buffer B (17-22 min) and eluted by increasing buffer B from 5-28% (22-80 min) and 28-40% (80-85 min), followed by a 5 min wash to 95 % and a 5 min regeneration to 5%. Survey scans of peptide precursors from 375 to 1500 m/z were performed at 120K resolution (at 200 m/z) with a 4x10<sup>5</sup> ion count target. Tandem mass spectrometry was performed by isolation with the quadrupole with isolation window 0.7, HCD fragmentation with normalized collision energy of 30, and rapid scan mass spectrometry analysis in the ion trap. The MS2 ion count target was set to 3x10<sup>4</sup>, and the max injection time was 20ms. Only those precursors with charge state 2–7 were sampled for MS2. The dynamic exclusion duration was set to 20s with a 10ppm tolerance around the selected precursor and its isotopes. Monoisotopic precursor selection was turned on. The instrument was run in top speed mode with 1s cycles. All data were acquired with Xcalibur SII software.</p></sec><sec id="S22"><title>Mass spectrometry analysis</title><p id="P36">Raw mass spectrometry files were processed with the MaxQuant computational platform, version 1.6.2.10. Proteins and peptides were identified using the Andromeda search engine by querying the reviewed human Uniprot database (downloaded 09-22-2023 20426 entries). Standard settings with the additional options match between runs, and unique peptides for quantification were selected. The generated ‘proteingroups.txt’ data were imported in R4.30/Rstudio 2024.04.1. ‘reverse’, ‘potential contaminants’ and ‘only identified by site’ peptides were filtered out and label free quantification values were log2 transformed.</p><p id="P37">Missing values were imputed by a normal distribution (width=0.3, shift = 1.8), assuming these proteins were close to the detection limit. Statistical analyses were performed using moderated t-tests in the LIMMA package. A Benjamini-Hochberg adjusted P value &lt;0.05 and absolute log2 fold change &gt;1 was considered statistically significant and relevant.</p><p id="P38">For supervised classification, we generated theoretical profiles in which conditions of interest intensities were set to an arbitrary high and low in all other samples <sup><xref ref-type="bibr" rid="R38">38</xref></sup>. These profiles were correlated with all statistically significant proteins. Correlation between data and disorder specific theoretical protein profiles was performed using a Pearson correlation coefficient of 0.5 and Benjamini-Hochberg adjusted P value &lt;0.05 was used as threshold. The R package ggplot2 was used for graphical representations.</p></sec><sec id="S23"><title>Genetic modification of T cells with Cas9 RNPs</title><p id="P39">crRNAs were designed in Benchling (<ext-link ext-link-type="uri" xlink:href="https://benchling.com;">https://benchling.com;</ext-link> <xref ref-type="supplementary-material" rid="SD5">Appendix B</xref>). Cas9 RNP production and T cell nucleofection was performed as previously described <sup><xref ref-type="bibr" rid="R35">35</xref></sup>. Briefly, Alt-R crRNA and tracrRNA were reconstituted to 100 μM in Nuclease Free Duplex buffer (all IDT). As a negative control, nontargeting negative control crRNA #1 was used (IDT). Oligos were mixed at equimolar ratios (i.e. 4.5 mL total crRNA + 4.5 mL tracrRNA) in nuclease-free PCR tubes and denatured by heating at 95°C for 5 min in a thermocycler. Nucleic acids were cooled down to room temperature prior to mixing them with 30 μg Alt-R™ S.p. Cas9 Nuclease V3 (IDT) to produce Cas9 ribonuclear proteins (RNPs). Mixture was incubated at room temperature for at least 10 min prior to nucleofection. For nucleofection, human CD3<sup>+</sup> T cells were activated for 48 h with αCD3/αCD28 and washed twice with PBS. Cells were resuspended in P2 buffer (Lonza). Cells were electroporated in 16-well strips in a 4D Nucleofector X unit (Lonza) with program EH100 for human T cells &amp;P2 buffer. Knockout efficiency was determined on day 5 days after electroporation by Western blot.</p></sec><sec id="S24"><title>Immunoblotting</title><p id="P40">Cell lysates (1x10<sup>6</sup> cells per sample) were prepared by standard procedures using RIPA lysis buffer (Thermo) supplemented with protease and phosphatase inhibitors (Thermo). Lysates were run on 4–12% SDS-PAGE (Thermo). SDS-PAGE gels were directly transferred onto nitrocellulose membranes (iBlot2, Thermo). Subsequently, membranes were blocked with 5% BSA TBST solution (Fraction V, Sigma). Membranes were stained with α-EDF1 (Proteintech), α-TCP1 (91A, Thermo Fisher Scientific) α-LSM7 (Proteintech), α-PRMT1 (A33, Cell Signalling Technology), α-DDX21 (Proteintech) (or α-RhoGDI (MAB9959, Abnova), followed by α-Rabbit (4050-05, Southern Biotech) or α-Mouse (1031-05, Southern Biotech) HRP-conjugated secondary antibodies.</p></sec><sec id="S25"><title>Quantification and statistical analysis</title><p id="P41">Results are shown as mean ± SD. Statistical analysis was performed with GraphPad Prism 10 with Wilcoxon two-tailed ratio paired or unpaired Student’s t test when comparing two groups, or with one-way ANOVA test with Dunnett correction when comparing more than two groups. p values &lt; 0.05 were considered statistically significant.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplemental Figures</label><media xlink:href="EMS199179-supplement-Supplemental_Figures.pdf" mimetype="application" mime-subtype="pdf" id="d20aAcEbB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>Supplemental Table 1</label><media xlink:href="EMS199179-supplement-Supplemental_Table_1.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d20aAcEcB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD3"><label>Supplemental Table 2</label><media xlink:href="EMS199179-supplement-Supplemental_Table_2.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d20aAcEdB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD4"><label>Supplemental Table 3</label><media xlink:href="EMS199179-supplement-Supplemental_Table_3.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d20aAcEeB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD5"><label>Appendix</label><media xlink:href="EMS199179-supplement-Appendix.pdf" mimetype="application" mime-subtype="pdf" id="d20aAcEfB" position="anchor"/></supplementary-material></sec></body><back><ack id="S26"><title>Acknowledgements</title><p>We thank G. Stoecklin (University of Heidelberg) for the 4xS1m aptamer construct; L. Wardak and A. Guislain for technical help; V. Lattanzio, N. Zandhuis, K. Bresser, for critical reading of the manuscript. This research was supported by European Research Council consolidator award PRINTERS 817533, and Oncode Institute, all to M.C.W.</p></ack><sec id="S27" sec-type="data-availability"><title>Data Code And Availability</title><list list-type="bullet" id="L1"><list-item><p>The mass spectrometry proteomics data of the RNA Aptamer Pulldown have been deposited to the ProteomeXchange Consortium via the PRIDE<sup><xref ref-type="bibr" rid="R55">55</xref></sup> partner repository with the dataset identifier PXD056415</p></list-item><list-item><p>This paper does not report original custom code. All codes used in this paper are available from the lead contact upon request.</p></list-item><list-item><p>Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.</p></list-item></list></sec><fn-group><fn id="FN1" fn-type="con"><p id="P42"><bold>Author Contributions</bold></p><p id="P43">Conceptualization, A.P.J and M.C.W.; Methodology, A.P.J., B.P., and M.C.W.; Investigation, A.P.J., B.P., J.Z., and F.P.J.v.A.; Formal Analysis, A.P.J., A.J.H., and K.R.; Validation, A.P.J., J.Z., and A.B.; Writing-Original Draft, A.P.J and M.C.W.; Writing – Review &amp; Editing, A.P.J., B.P., A.J.H., F.P.J.v.A., and M.C.W.; Supervision, M.C.W.; Funding Acquisition, M.C.W.</p></fn><fn id="FN2" fn-type="conflict"><p id="P44"><bold>Declaration Of Interest</bold></p><p id="P45">The authors declare no competing interests.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salerno</surname><given-names>F</given-names></name><name><surname>Turner</surname><given-names>M</given-names></name><name><surname>Wolkers</surname><given-names>MC</given-names></name></person-group><article-title>Dynamic post-transcriptional events governing CD8+ T cell homeostasis and effector function</article-title><source>Trends Immunol</source><year>2020</year><volume>41</volume><fpage>240</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">32007423</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolet</surname><given-names>BP</given-names></name><name><surname>Zandhuis</surname><given-names>ND</given-names></name><name><surname>Lattanzio</surname><given-names>VM</given-names></name><name><surname>Wolkers</surname><given-names>MC</given-names></name></person-group><article-title>Sequence determinants as key regulators in gene expression of T cells</article-title><year>2021</year><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="pmcid">PMC9292449</pub-id><pub-id pub-id-type="pmid">34486113</pub-id><pub-id pub-id-type="doi">10.1111/imr.13021</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>JD</given-names></name><name><surname>Delgoffe</surname><given-names>GM</given-names></name></person-group><article-title>The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and Metabolism</article-title><source>Immunity</source><year>2010</year><volume>33</volume><fpage>301</fpage><lpage>311</lpage><pub-id pub-id-type="pmcid">PMC2962404</pub-id><pub-id pub-id-type="pmid">20870173</pub-id><pub-id pub-id-type="doi">10.1016/j.immuni.2010.09.002</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>H</given-names></name></person-group><article-title>Regulation and function of mTOR signalling in T cell fate decisions</article-title><source>Nat Rev Immunol</source><year>2012</year><volume>12</volume><fpage>325</fpage><lpage>338</lpage><pub-id pub-id-type="pmcid">PMC3417069</pub-id><pub-id pub-id-type="pmid">22517423</pub-id><pub-id pub-id-type="doi">10.1038/nri3198</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollizzi</surname><given-names>KN</given-names></name><name><surname>Patel</surname><given-names>CH</given-names></name><name><surname>Sun</surname><given-names>IH</given-names></name><name><surname>Oh</surname><given-names>MH</given-names></name><name><surname>Waickman</surname><given-names>AT</given-names></name><name><surname>Wen</surname><given-names>J</given-names></name><name><surname>Delgoffe</surname><given-names>GM</given-names></name><name><surname>Powell</surname><given-names>JD</given-names></name></person-group><article-title>mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation</article-title><source>J Clin Invest</source><year>2015</year><volume>125</volume><fpage>2090</fpage><lpage>2108</lpage><pub-id pub-id-type="pmcid">PMC4463194</pub-id><pub-id pub-id-type="pmid">25893604</pub-id><pub-id pub-id-type="doi">10.1172/JCI77746</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hukelmann</surname><given-names>JL</given-names></name><name><surname>Anderson</surname><given-names>KE</given-names></name><name><surname>Sinclair</surname><given-names>LV</given-names></name><name><surname>Grzes</surname><given-names>KM</given-names></name><name><surname>Murillo</surname><given-names>AB</given-names></name><name><surname>Hawkins</surname><given-names>PT</given-names></name><name><surname>Stephens</surname><given-names>LR</given-names></name><name><surname>Lamond</surname><given-names>AI</given-names></name><name><surname>Cantrell</surname><given-names>DA</given-names></name></person-group><article-title>The cytotoxic T cell proteome and its shaping by the kinase mTOR</article-title><source>Nat Immunol</source><year>2016</year><volume>17</volume><fpage>104</fpage><lpage>112</lpage><pub-id pub-id-type="pmcid">PMC4685757</pub-id><pub-id pub-id-type="pmid">26551880</pub-id><pub-id pub-id-type="doi">10.1038/ni.3314</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jurgens</surname><given-names>AP</given-names></name><name><surname>Popovic</surname><given-names>B</given-names></name><name><surname>Wolkers</surname><given-names>MC</given-names></name></person-group><article-title>T cells at work: How post-transcriptional mechanisms control T cell homeostasis and activation</article-title><source>Eur J Immunol</source><year>2021</year><volume>51</volume><fpage>2178</fpage><lpage>2187</lpage><pub-id pub-id-type="pmcid">PMC8457102</pub-id><pub-id pub-id-type="pmid">34180545</pub-id><pub-id pub-id-type="doi">10.1002/eji.202049055</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villa</surname><given-names>E</given-names></name><name><surname>Sahu</surname><given-names>U</given-names></name><name><surname>O’Hara</surname><given-names>BP</given-names></name><name><surname>Ali</surname><given-names>ES</given-names></name><name><surname>Helmin</surname><given-names>KA</given-names></name><name><surname>Asara</surname><given-names>JM</given-names></name><name><surname>Gao</surname><given-names>P</given-names></name><name><surname>Singer</surname><given-names>BD</given-names></name><name><surname>Ben-Sahra</surname><given-names>I</given-names></name></person-group><article-title>mTORC1 stimulates cell growth through SAM synthesis and m6A mRNA-dependent control of protein synthesis</article-title><source>Mol Cell</source><year>2021</year><volume>81</volume><fpage>2076</fpage><lpage>2093</lpage><elocation-id>e9</elocation-id><pub-id pub-id-type="pmcid">PMC8141029</pub-id><pub-id pub-id-type="pmid">33756106</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2021.03.009</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>C</given-names></name><name><surname>Erhard</surname><given-names>F</given-names></name><name><surname>Binotti</surname><given-names>B</given-names></name><name><surname>Buchberger</surname><given-names>A</given-names></name><name><surname>Vogel</surname><given-names>J</given-names></name><name><surname>Fischer</surname><given-names>U</given-names></name></person-group><article-title>An unusual mode of baseline translation adjusts cellular protein synthesis capacity to metabolic needs</article-title><source>Cell Rep</source><year>2022</year><volume>41</volume><elocation-id>111467</elocation-id><pub-id pub-id-type="pmid">36223745</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Shaw</surname><given-names>TI</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Blanco</surname><given-names>DB</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Cho</surname><given-names>JH</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Rankin</surname><given-names>S</given-names></name><etal/></person-group><article-title>Integrative proteomics and phosphoproteomics profiling reveals dynamic signaling networks and bioenergetics pathways underlying T cell activation</article-title><source>Immunity</source><year>2017</year><volume>46</volume><fpage>488</fpage><lpage>503</lpage><pub-id pub-id-type="pmcid">PMC5466820</pub-id><pub-id pub-id-type="pmid">28285833</pub-id><pub-id pub-id-type="doi">10.1016/j.immuni.2017.02.010</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchingo</surname><given-names>JM</given-names></name><name><surname>Sinclair</surname><given-names>LV</given-names></name><name><surname>Howden</surname><given-names>AJ</given-names></name><name><surname>Cantrell</surname><given-names>DA</given-names></name></person-group><article-title>Quantitative analysis of how myc controls t cell proteomes and metabolic pathways during t cell activation</article-title><source>eLife</source><year>2020</year><volume>9</volume><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="pmcid">PMC7056270</pub-id><pub-id pub-id-type="pmid">32022686</pub-id><pub-id pub-id-type="doi">10.7554/eLife.53725</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>T</given-names></name><name><surname>Jin</surname><given-names>W</given-names></name><name><surname>Zoppi</surname><given-names>G</given-names></name><name><surname>Vogel</surname><given-names>IA</given-names></name><name><surname>Akhmedov</surname><given-names>M</given-names></name><name><surname>Bleck</surname><given-names>CKE</given-names></name><name><surname>Beltraminelli</surname><given-names>T</given-names></name><name><surname>Rieckmann</surname><given-names>JC</given-names></name><name><surname>Ramirez</surname><given-names>NJ</given-names></name><name><surname>Benevento</surname><given-names>M</given-names></name><etal/></person-group><article-title>Dynamics in protein translation sustaining T cell preparedness</article-title><source>Nat Immunol</source><year>2020</year><volume>21</volume><fpage>927</fpage><lpage>937</lpage><pub-id pub-id-type="pmcid">PMC7610365</pub-id><pub-id pub-id-type="pmid">32632289</pub-id><pub-id pub-id-type="doi">10.1038/s41590-020-0714-5</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchingo</surname><given-names>JM</given-names></name><name><surname>Cantrell</surname><given-names>DA</given-names></name></person-group><article-title>Protein synthesis, degradation, and energy metabolism in T cell immunity</article-title><source>Cell Mol Immunol</source><year>2022</year><pub-id pub-id-type="pmcid">PMC8891282</pub-id><pub-id pub-id-type="pmid">34983947</pub-id><pub-id pub-id-type="doi">10.1038/s41423-021-00792-8</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carballo</surname><given-names>E</given-names></name><name><surname>Lai</surname><given-names>WS</given-names></name><name><surname>Blackshear</surname><given-names>PJ</given-names></name></person-group><article-title>Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin</article-title><source>Science</source><year>1998</year><volume>281</volume><fpage>1001</fpage><lpage>1005</lpage><pub-id pub-id-type="pmid">9703499</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kontoyiannis</surname><given-names>D</given-names></name><name><surname>Pasparakis</surname><given-names>M</given-names></name><name><surname>Pizarro</surname><given-names>TT</given-names></name><name><surname>Cominelli</surname><given-names>F</given-names></name><name><surname>Kollias</surname><given-names>G</given-names></name></person-group><article-title>Impaired On/Off Regulation of TNF Biosynthesis in Mice Lacking TNF AU-Rich Elements: Implications for Joint and Gut-Associated Immunopathologies</article-title><source>Immunity</source><year>1999</year><volume>10</volume><fpage>287</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">10204494</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogilvie</surname><given-names>RL</given-names></name><name><surname>SternJohn</surname><given-names>JR</given-names></name><name><surname>Rattenbacher</surname><given-names>B</given-names></name><name><surname>Vlasova</surname><given-names>IA</given-names></name><name><surname>Williams</surname><given-names>DA</given-names></name><name><surname>Hau</surname><given-names>HH</given-names></name><name><surname>Blackshear</surname><given-names>PJ</given-names></name><name><surname>Bohjanen</surname><given-names>PR</given-names></name></person-group><article-title>Tristetraprolin Mediates Interferon—Y mRNA Decay</article-title><source>J Biol Chem</source><year>2009</year><volume>284</volume><fpage>11216</fpage><lpage>11223</lpage><pub-id pub-id-type="pmcid">PMC2670126</pub-id><pub-id pub-id-type="pmid">19258311</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M901229200</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodge</surname><given-names>DL</given-names></name><name><surname>Berthet</surname><given-names>C</given-names></name><name><surname>Coppola</surname><given-names>V</given-names></name><name><surname>Kastenmuller</surname><given-names>W</given-names></name><name><surname>Buschman</surname><given-names>MD</given-names></name><name><surname>Schaughency</surname><given-names>PM</given-names></name><name><surname>Shirota</surname><given-names>H</given-names></name><name><surname>Scarzello</surname><given-names>AJ</given-names></name><name><surname>Subleski</surname><given-names>JJ</given-names></name><name><surname>Anver</surname><given-names>MR</given-names></name><etal/></person-group><article-title>IFN-gamma AU-rich element removal promotes chronic IFN-gamma expression and autoimmunity in mice</article-title><source>J Autoimmun</source><year>2014</year><volume>53</volume><fpage>33</fpage><lpage>45</lpage><pub-id pub-id-type="pmcid">PMC4148478</pub-id><pub-id pub-id-type="pmid">24583068</pub-id><pub-id pub-id-type="doi">10.1016/j.jaut.2014.02.003</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salerno</surname><given-names>F</given-names></name><name><surname>Engels</surname><given-names>S</given-names></name><name><surname>van den Biggelaar</surname><given-names>M</given-names></name><name><surname>van Alphen</surname><given-names>FPJ</given-names></name><name><surname>Guislain</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Hodge</surname><given-names>DL</given-names></name><name><surname>Bell</surname><given-names>SE</given-names></name><name><surname>Medema</surname><given-names>JP</given-names></name><name><surname>von Lindern</surname><given-names>M</given-names></name><etal/></person-group><article-title>Translational repression of pre-formed cytokine-encoding mRNA prevents chronic activation of memory T cells</article-title><source>Nat Immunol</source><year>2018</year><volume>19</volume><fpage>828</fpage><lpage>837</lpage><pub-id pub-id-type="pmcid">PMC6643272</pub-id><pub-id pub-id-type="pmid">29988089</pub-id><pub-id pub-id-type="doi">10.1038/s41590-018-0155-6</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayr</surname><given-names>C</given-names></name></person-group><article-title>What are 3’ utrs doing?</article-title><source>Cold Spring Harb Perspect Biol</source><year>2019</year><volume>11</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="pmcid">PMC6771366</pub-id><pub-id pub-id-type="pmid">30181377</pub-id><pub-id pub-id-type="doi">10.1101/cshperspect.a034728</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thoreen</surname><given-names>CC</given-names></name><name><surname>Chantranupong</surname><given-names>L</given-names></name><name><surname>Keys</surname><given-names>HR</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Gray</surname><given-names>NS</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><article-title>A unifying model for mTORC1-mediated regulation of mRNA translation</article-title><source>Nature</source><year>2012</year><volume>485</volume><fpage>109</fpage><lpage>113</lpage><pub-id pub-id-type="pmcid">PMC3347774</pub-id><pub-id pub-id-type="pmid">22552098</pub-id><pub-id pub-id-type="doi">10.1038/nature11083</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Freeberg</surname><given-names>MA</given-names></name><name><surname>Han</surname><given-names>T</given-names></name><name><surname>Kamath</surname><given-names>A</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Fukuda</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>JK</given-names></name><name><surname>Inoki</surname><given-names>K</given-names></name></person-group><article-title>LARP1 functions as a molecular switch for mTORC1-mediated translation of an essential class of mRNAs</article-title><source>eLife</source><year>2017</year><volume>6</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="pmcid">PMC5484620</pub-id><pub-id pub-id-type="pmid">28650797</pub-id><pub-id pub-id-type="doi">10.7554/eLife.25237</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philippe</surname><given-names>L</given-names></name><name><surname>van den Elzen</surname><given-names>AMG</given-names></name><name><surname>Watson</surname><given-names>MJ</given-names></name><name><surname>Thoreen</surname><given-names>CC</given-names></name></person-group><article-title>Global analysis of LARP1 translation targets reveals tunable and dynamic features of 5’ TOP motifs</article-title><source>Proc Natl Acad Sci U S A</source><year>2020</year><volume>117</volume><fpage>5319</fpage><lpage>5328</lpage><pub-id pub-id-type="pmcid">PMC7071917</pub-id><pub-id pub-id-type="pmid">32094190</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1912864117</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>AJ</given-names></name><name><surname>Thoreen</surname><given-names>CC</given-names></name><name><surname>Dedeic</surname><given-names>Z</given-names></name><name><surname>Chettle</surname><given-names>J</given-names></name><name><surname>Roux</surname><given-names>PP</given-names></name><name><surname>Blagden</surname><given-names>SP</given-names></name></person-group><article-title>Controversies around the function of LARP1</article-title><source>RNA Biol</source><year>2021</year><volume>18</volume><fpage>207</fpage><lpage>217</lpage><pub-id pub-id-type="pmcid">PMC7928164</pub-id><pub-id pub-id-type="pmid">32233986</pub-id><pub-id pub-id-type="doi">10.1080/15476286.2020.1733787</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>J-W</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Yeh</surname><given-names>H-S</given-names></name><name><surname>De Jong</surname><given-names>EP</given-names></name><name><surname>Jun</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>K-H</given-names></name><name><surname>Bae</surname><given-names>SS</given-names></name><name><surname>Beckman</surname><given-names>K</given-names></name><name><surname>Hwang</surname><given-names>TH</given-names></name><name><surname>Kim</surname><given-names>K-S</given-names></name><etal/></person-group><article-title>mRNA 3’-UTR shortening is a molecular signature of mTORC1 activation</article-title><source>Nat Commun</source><year>2015</year><volume>6</volume><elocation-id>7218</elocation-id><pub-id pub-id-type="pmid">26074333</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masopust</surname><given-names>D</given-names></name><name><surname>Vezys</surname><given-names>V</given-names></name><name><surname>Marzo</surname><given-names>AL</given-names></name><name><surname>Lefrangois</surname><given-names>L</given-names></name></person-group><article-title>Preferential Localization of Effector Memory Cells in Nonlymphoid Tissue</article-title><source>Science</source><year>2001</year><volume>291</volume><fpage>2413</fpage><lpage>2417</lpage><pub-id pub-id-type="pmid">11264538</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Q</given-names></name><name><surname>Bagheri</surname><given-names>N</given-names></name><name><surname>Bradshaw</surname><given-names>EM</given-names></name><name><surname>Hafler</surname><given-names>DA</given-names></name><name><surname>Lauffenburger</surname><given-names>DA</given-names></name><name><surname>Love</surname><given-names>JC</given-names></name></person-group><article-title>Polyfunctional responses by human T cells result from sequential release of cytokines</article-title><source>Proc Natl Acad Sci U S A</source><year>2012</year><pub-id pub-id-type="pmcid">PMC3277116</pub-id><pub-id pub-id-type="pmid">22160692</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1117194109</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolet</surname><given-names>BP</given-names></name><name><surname>Guislain</surname><given-names>A</given-names></name><name><surname>Wolkers</surname><given-names>MC</given-names></name></person-group><article-title>Combined Single-Cell Measurement of Cytokine mRNA and Protein Identifies T Cells with Persistent Effector Function</article-title><source>J Immunol</source><year>2017</year><volume>198</volume><fpage>962</fpage><lpage>970</lpage><pub-id pub-id-type="pmid">27927969</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thoreen</surname><given-names>CC</given-names></name><name><surname>Kang</surname><given-names>SA</given-names></name><name><surname>Chang</surname><given-names>JW</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Reichling</surname><given-names>LJ</given-names></name><name><surname>Sim</surname><given-names>T</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name><name><surname>Gray</surname><given-names>NS</given-names></name></person-group><article-title>An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1</article-title><source>J Biol Chem</source><year>2009</year><volume>284</volume><fpage>8023</fpage><lpage>8032</lpage><pub-id pub-id-type="pmcid">PMC2658096</pub-id><pub-id pub-id-type="pmid">19150980</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M900301200</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukhopadhyay</surname><given-names>S</given-names></name><name><surname>Frias</surname><given-names>MA</given-names></name><name><surname>Chatterjee</surname><given-names>A</given-names></name><name><surname>Yellen</surname><given-names>P</given-names></name><name><surname>Foster</surname><given-names>DA</given-names></name></person-group><article-title>The Enigma of Rapamycin Dosage</article-title><source>Mol Cancer Ther</source><year>2016</year><volume>15</volume><fpage>347</fpage><lpage>353</lpage><pub-id pub-id-type="pmcid">PMC4783198</pub-id><pub-id pub-id-type="pmid">26916116</pub-id><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-15-0720</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Erie</surname><given-names>DJ</given-names></name></person-group><article-title>Widespread Effects of Chemokine 3’ Untranslated Regions on mRNA Degradation and Protein Production in Human Cells</article-title><source>J Immunol</source><year>2018</year><volume>201</volume><fpage>1053</fpage><lpage>1061</lpage><pub-id pub-id-type="pmcid">PMC6057839</pub-id><pub-id pub-id-type="pmid">29907706</pub-id><pub-id pub-id-type="doi">10.4049/jimmunol.1800114</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popovic</surname><given-names>B</given-names></name><name><surname>Nicolet</surname><given-names>BP</given-names></name><name><surname>Guislain</surname><given-names>A</given-names></name><name><surname>Engels</surname><given-names>S</given-names></name><name><surname>Jurgens</surname><given-names>AP</given-names></name><name><surname>Paravinja</surname><given-names>N</given-names></name><name><surname>Freen-van Heeren</surname><given-names>JJ</given-names></name><name><surname>Van Alphen</surname><given-names>FPJ</given-names></name><name><surname>van Den Biggelaar</surname><given-names>M</given-names></name><name><surname>Salerno</surname><given-names>F</given-names></name><etal/></person-group><article-title>Time-dependent regulation of cytokine production by RNA binding proteins defines T cell effector function</article-title><source>Cell Rep</source><year>2023</year><volume>42</volume><elocation-id>112419</elocation-id><pub-id pub-id-type="pmcid">PMC10242446</pub-id><pub-id pub-id-type="pmid">37074914</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2023.112419</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tcherkezian</surname><given-names>J</given-names></name><name><surname>Cargnello</surname><given-names>M</given-names></name><name><surname>Romeo</surname><given-names>Y</given-names></name><name><surname>Huttlin</surname><given-names>EL</given-names></name><name><surname>Lavoie</surname><given-names>G</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name><name><surname>Roux</surname><given-names>PP</given-names></name></person-group><article-title>Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5’TOP mRNA translation</article-title><source>Genes Dev</source><year>2014</year><volume>28</volume><fpage>357</fpage><lpage>371</lpage><pub-id pub-id-type="pmcid">PMC3937514</pub-id><pub-id pub-id-type="pmid">24532714</pub-id><pub-id pub-id-type="doi">10.1101/gad.231407.113</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caput</surname><given-names>D</given-names></name><name><surname>Beutler</surname><given-names>B</given-names></name><name><surname>Hartog</surname><given-names>K</given-names></name><name><surname>Thayer</surname><given-names>R</given-names></name><name><surname>Brown-Shimer</surname><given-names>S</given-names></name><name><surname>Cerami</surname><given-names>A</given-names></name></person-group><article-title>Identification of a common nucleotide sequence in the 3’-untranslated region of mRNA molecules specifying inflammatory mediators</article-title><source>Proc Natl Acad Sci</source><year>1986</year><volume>83</volume><fpage>1670</fpage><lpage>1674</lpage><pub-id pub-id-type="pmcid">PMC323145</pub-id><pub-id pub-id-type="pmid">2419912</pub-id><pub-id pub-id-type="doi">10.1073/pnas.83.6.1670</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barreau</surname><given-names>C</given-names></name></person-group><article-title>AU-rich elements and associated factors: are there unifying principles?</article-title><source>Nucleic Acids Res</source><year>2005</year><volume>33</volume><fpage>7138</fpage><lpage>7150</lpage><pub-id pub-id-type="pmcid">PMC1325018</pub-id><pub-id pub-id-type="pmid">16391004</pub-id><pub-id pub-id-type="doi">10.1093/nar/gki1012</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freen-van Heeren</surname><given-names>JJ</given-names></name><name><surname>Popovic</surname><given-names>B</given-names></name><name><surname>Guislain</surname><given-names>A</given-names></name><name><surname>Wolkers</surname><given-names>MC</given-names></name></person-group><article-title>Human T cells employ conserved AU-rich elements to fine-tune IFN-γ production</article-title><source>Eur J Immunol</source><year>2020</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmcid">PMC7384093</pub-id><pub-id pub-id-type="pmid">32112565</pub-id><pub-id pub-id-type="doi">10.1002/eji.201948458</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leppek</surname><given-names>K</given-names></name><name><surname>Schott</surname><given-names>J</given-names></name><name><surname>Reitter</surname><given-names>S</given-names></name><name><surname>Poetz</surname><given-names>F</given-names></name><name><surname>Hammond</surname><given-names>MC</given-names></name><name><surname>Stoecklin</surname><given-names>G</given-names></name></person-group><article-title>Roquin promotes constitutive mrna decay via a conserved class of stem-loop recognition motifs</article-title><source>Cell</source><year>2013</year><volume>153</volume><fpage>869</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">23663784</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leppek</surname><given-names>K</given-names></name><name><surname>Stoecklin</surname><given-names>G</given-names></name></person-group><article-title>An optimized streptavidin-binding RNA aptamer for purification of ribonucleoprotein complexes identifies novel ARE-binding proteins</article-title><source>Nucleic Acids Res</source><year>2014</year><volume>42</volume><pub-id pub-id-type="pmcid">PMC3902943</pub-id><pub-id pub-id-type="pmid">24157833</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkt956</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreft</surname><given-names>IC</given-names></name><name><surname>Huisman</surname><given-names>EJ</given-names></name><name><surname>Cnossen</surname><given-names>MH</given-names></name><name><surname>Van Alphen</surname><given-names>FPJ</given-names></name><name><surname>van Der Zwaan</surname><given-names>C</given-names></name><name><surname>Van Leeuwen</surname><given-names>K</given-names></name><name><surname>Van Spaendonk</surname><given-names>R</given-names></name><name><surname>Porcelijn</surname><given-names>L</given-names></name><name><surname>Veen</surname><given-names>CSB</given-names></name><name><surname>van Den Biggelaar</surname><given-names>M</given-names></name><etal/></person-group><article-title>Proteomic landscapes of inherited platelet disorders with different etiologies</article-title><source>J Thromb Haemost</source><year>2023</year><volume>21</volume><fpage>359</fpage><lpage>372</lpage><elocation-id>e3</elocation-id><pub-id pub-id-type="pmid">36700500</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>LM</given-names></name><name><surname>Remis</surname><given-names>D</given-names></name></person-group><article-title>Five of the nine genetically defined regions of mouse <italic>t</italic> haplotypes are involved in transmission ratio distortion</article-title><source>Genet Res</source><year>1987</year><volume>49</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">3569907</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayya</surname><given-names>V</given-names></name><name><surname>Lundgren</surname><given-names>DH</given-names></name><name><surname>Hwang</surname><given-names>S-I</given-names></name><name><surname>Rezaul</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Eng</surname><given-names>JK</given-names></name><name><surname>Rodionov</surname><given-names>V</given-names></name><name><surname>Han</surname><given-names>DK</given-names></name></person-group><article-title>Quantitative Phosphoproteomic Analysis of T Cell Receptor Signaling Reveals System-Wide Modulation of Protein-Protein Interactions</article-title><source>Sci Signal</source><year>2009</year><volume>84</volume><pub-id pub-id-type="pmid">19690332</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollizzi</surname><given-names>KN</given-names></name><name><surname>Powell</surname><given-names>JD</given-names></name></person-group><article-title>Regulation of T cells by mTOR: The known knowns and the known unknowns</article-title><source>Trends Immunol</source><year>2015</year><volume>36</volume><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="pmcid">PMC4290883</pub-id><pub-id pub-id-type="pmid">25522665</pub-id><pub-id pub-id-type="doi">10.1016/j.it.2014.11.005</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoki</surname><given-names>K</given-names></name><name><surname>Adachi</surname><given-names>S</given-names></name><name><surname>Homoto</surname><given-names>M</given-names></name><name><surname>Kusano</surname><given-names>H</given-names></name><name><surname>Koike</surname><given-names>K</given-names></name><name><surname>Natsume</surname><given-names>T</given-names></name></person-group><article-title>LARP1 specifically recognizes the 3’ terminus of poly(A) mRNA</article-title><source>FEBS Lett</source><year>2013</year><volume>587</volume><fpage>2173</fpage><lpage>2178</lpage><pub-id pub-id-type="pmid">23711370</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahr</surname><given-names>RM</given-names></name><name><surname>Mack</surname><given-names>SM</given-names></name><name><surname>Heroux</surname><given-names>A</given-names></name><name><surname>Blagden</surname><given-names>SP</given-names></name><name><surname>Bousquet-Antonelli</surname><given-names>C</given-names></name><name><surname>Deragon</surname><given-names>JM</given-names></name><name><surname>Berman</surname><given-names>AJ</given-names></name></person-group><article-title>The La-related protein 1-specific domain repurposes HEAT-like repeats to directly bind a 5’TOP sequence</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><fpage>8077</fpage><lpage>8088</lpage><pub-id pub-id-type="pmcid">PMC4652764</pub-id><pub-id pub-id-type="pmid">26206669</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkv748</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonseca</surname><given-names>BD</given-names></name><name><surname>Zakaria</surname><given-names>C</given-names></name><name><surname>Jia</surname><given-names>J-J</given-names></name><name><surname>Graber</surname><given-names>TE</given-names></name><name><surname>Svitkin</surname><given-names>Y</given-names></name><name><surname>Tahmasebi</surname><given-names>S</given-names></name><name><surname>Healy</surname><given-names>D</given-names></name><name><surname>Hoang</surname><given-names>H-D</given-names></name><name><surname>Jensen</surname><given-names>JM</given-names></name><name><surname>Diao</surname><given-names>IT</given-names></name><etal/></person-group><article-title>La-related Protein 1 (LARP1) Represses Terminal Oligopyrimidine (TOP) mRNA Translation Downstream of mTOR Complex 1 (mTORC1)</article-title><source>J Biol Chem</source><year>2015</year><volume>290</volume><fpage>15996</fpage><lpage>16020</lpage><pub-id pub-id-type="pmcid">PMC4481205</pub-id><pub-id pub-id-type="pmid">25940091</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M114.621730</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herranz</surname><given-names>N</given-names></name><name><surname>Gallage</surname><given-names>S</given-names></name><name><surname>Mellone</surname><given-names>M</given-names></name><name><surname>Wuestefeld</surname><given-names>T</given-names></name><name><surname>Klotz</surname><given-names>S</given-names></name><name><surname>Hanley</surname><given-names>CJ</given-names></name><name><surname>Raguz</surname><given-names>S</given-names></name><name><surname>Acosta</surname><given-names>JC</given-names></name><name><surname>Innes</surname><given-names>AJ</given-names></name><name><surname>Banito</surname><given-names>A</given-names></name><etal/></person-group><article-title>mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype</article-title><source>Nat Cell Biol</source><year>2015</year><volume>17</volume><fpage>1205</fpage><lpage>1217</lpage><pub-id pub-id-type="pmcid">PMC4589897</pub-id><pub-id pub-id-type="pmid">26280535</pub-id><pub-id pub-id-type="doi">10.1038/ncb3225</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calo</surname><given-names>E</given-names></name><name><surname>Flynn</surname><given-names>RA</given-names></name><name><surname>Martin</surname><given-names>L</given-names></name><name><surname>Spitale</surname><given-names>RC</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Wysocka</surname><given-names>J</given-names></name></person-group><article-title>RNA helicase DDX21 coordinates transcription and ribosomal RNA processing</article-title><source>Nature</source><year>2015</year><volume>518</volume><fpage>249</fpage><lpage>253</lpage><pub-id pub-id-type="pmcid">PMC4827702</pub-id><pub-id pub-id-type="pmid">25470060</pub-id><pub-id pub-id-type="doi">10.1038/nature13923</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>ME</given-names></name><name><surname>Bradstreet</surname><given-names>TR</given-names></name><name><surname>Webber</surname><given-names>AM</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Santeford</surname><given-names>A</given-names></name><name><surname>Harris</surname><given-names>KM</given-names></name><name><surname>Murphy</surname><given-names>MK</given-names></name><name><surname>Tran</surname><given-names>J</given-names></name><name><surname>Abdalla</surname><given-names>NM</given-names></name><name><surname>Schwarzkopf</surname><given-names>EA</given-names></name><etal/></person-group><article-title>The ZFP36 family of RNA binding proteins regulates homeostatic and autoreactive T cell responses</article-title><source>Sci Immunol</source><year>2022</year><volume>7</volume><elocation-id>eabo0981</elocation-id><pub-id pub-id-type="pmcid">PMC9832469</pub-id><pub-id pub-id-type="pmid">36269839</pub-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abo0981</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petkau</surname><given-names>G</given-names></name><name><surname>Mitchell</surname><given-names>TJ</given-names></name><name><surname>Chakraborty</surname><given-names>K</given-names></name><name><surname>Bell</surname><given-names>SE</given-names></name><name><surname>D’Angeli</surname><given-names>V</given-names></name><name><surname>Matheson</surname><given-names>L</given-names></name><name><surname>Turner</surname><given-names>DJ</given-names></name><name><surname>Saveliev</surname><given-names>A</given-names></name><name><surname>Gizlenci</surname><given-names>O</given-names></name><name><surname>Salerno</surname><given-names>F</given-names></name><etal/></person-group><article-title>The timing of differentiation and potency of CD8 effector function is set by RNA binding proteins</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><elocation-id>2274</elocation-id><pub-id pub-id-type="pmcid">PMC9046422</pub-id><pub-id pub-id-type="pmid">35477960</pub-id><pub-id pub-id-type="doi">10.1038/s41467-022-29979-x</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zandhuis</surname><given-names>ND</given-names></name><name><surname>Guislain</surname><given-names>A</given-names></name><name><surname>Popalzij</surname><given-names>A</given-names></name><name><surname>Engels</surname><given-names>S</given-names></name><name><surname>Popovic</surname><given-names>B</given-names></name><name><surname>Turner</surname><given-names>M</given-names></name><name><surname>Wolkers</surname><given-names>MC</given-names></name></person-group><article-title>Regulation of IFN-γ production by ZFP36L2 in T cells is time-dependent</article-title><source>Eur J Immunol</source><year>2024</year><elocation-id>2451018</elocation-id><pub-id pub-id-type="pmid">38980256</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandberg</surname><given-names>R</given-names></name><name><surname>Neilson</surname><given-names>JR</given-names></name><name><surname>Sarma</surname><given-names>A</given-names></name><name><surname>Sharp</surname><given-names>PA</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name></person-group><article-title>Proliferating cells express mRNAs with shortened 3’ untranslated regions and fewer microRNA target sites</article-title><source>Science</source><year>2008</year><volume>320</volume><fpage>1643</fpage><lpage>1647</lpage><pub-id pub-id-type="pmcid">PMC2587246</pub-id><pub-id pub-id-type="pmid">18566288</pub-id><pub-id pub-id-type="doi">10.1126/science.1155390</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gruber</surname><given-names>AR</given-names></name><name><surname>Martin</surname><given-names>G</given-names></name><name><surname>Muller</surname><given-names>P</given-names></name><name><surname>Schmidt</surname><given-names>A</given-names></name><name><surname>Gruber</surname><given-names>AJ</given-names></name><name><surname>Gumienny</surname><given-names>R</given-names></name><name><surname>Mittal</surname><given-names>N</given-names></name><name><surname>Jayachandran</surname><given-names>R</given-names></name><name><surname>Pieters</surname><given-names>J</given-names></name><name><surname>Keller</surname><given-names>W</given-names></name><etal/></person-group><article-title>Global 3’ UTR shortening has a limited effect on protein abundance in proliferating T cells</article-title><source>Nat Commun</source><year>2014</year><volume>5</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">25413384</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolet</surname><given-names>BP</given-names></name><name><surname>Jurgens</surname><given-names>AP</given-names></name><name><surname>Bresser</surname><given-names>K</given-names></name><name><surname>Guislain</surname><given-names>A</given-names></name><name><surname>Bradarig</surname><given-names>A</given-names></name><name><surname>Wolkers</surname><given-names>MC</given-names></name></person-group><article-title>Learning the sequence code of protein expression in human immune cells</article-title><source>Preprint</source><year>2024</year><pub-id pub-id-type="doi">10.1101/2023.09.01.555843</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccirillo</surname><given-names>CA</given-names></name><name><surname>Bjur</surname><given-names>E</given-names></name><name><surname>Topisirovic</surname><given-names>I</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name><name><surname>Larsson</surname><given-names>O</given-names></name></person-group><article-title>Translational control of immune responses: from transcripts to translatomes</article-title><source>Nat Immunol</source><year>2014</year><volume>15</volume><fpage>503</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">24840981</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rieckmann</surname><given-names>JC</given-names></name><name><surname>Geiger</surname><given-names>R</given-names></name><name><surname>Hornburg</surname><given-names>D</given-names></name><name><surname>Wolf</surname><given-names>T</given-names></name><name><surname>Kveler</surname><given-names>K</given-names></name><name><surname>Jarrossay</surname><given-names>D</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name><name><surname>Shen-Orr</surname><given-names>SS</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name><etal/></person-group><article-title>Social network architecture of human immune cells unveiled by quantitative proteomics</article-title><source>Nat Immunol</source><year>2017</year><volume>18</volume><fpage>583</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">28263321</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Riverol</surname><given-names>Y</given-names></name><name><surname>Bai</surname><given-names>J</given-names></name><name><surname>Bandla</surname><given-names>C</given-names></name><name><surname>Garda-Seisdedos</surname><given-names>D</given-names></name><name><surname>Hewapathirana</surname><given-names>S</given-names></name><name><surname>Kamatchinathan</surname><given-names>S</given-names></name><name><surname>Kundu</surname><given-names>DJ</given-names></name><name><surname>Prakash</surname><given-names>A</given-names></name><name><surname>Frericks-Zipper</surname><given-names>A</given-names></name><name><surname>Eisenacher</surname><given-names>M</given-names></name><etal/></person-group><article-title>The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences</article-title><source>Nucleic Acids Res</source><year>2022</year><volume>50</volume><fpage>D543</fpage><lpage>D552</lpage><pub-id pub-id-type="pmcid">PMC8728295</pub-id><pub-id pub-id-type="pmid">34723319</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkab1038</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolet</surname><given-names>BP</given-names></name><name><surname>Guislain</surname><given-names>A</given-names></name><name><surname>Van Alphen</surname><given-names>FPJ</given-names></name><name><surname>Gomez-Eerland</surname><given-names>R</given-names></name><name><surname>Schumacher</surname><given-names>TNM</given-names></name><name><surname>van Den Biggelaar</surname><given-names>M</given-names></name><name><surname>Wolkers</surname><given-names>MC</given-names></name></person-group><article-title>CD29 identifies IFN—Y—producing human CD8 <sup>+</sup> T cells with an increased cytotoxic potential</article-title><source>Proc Natl Acad Sci</source><year>2020</year><volume>117</volume><fpage>6686</fpage><lpage>6696</lpage><pub-id pub-id-type="pmcid">PMC7104308</pub-id><pub-id pub-id-type="pmid">32161126</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1913940117</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>mTOR boosts cytokine production through the cytokine 3’UTR independently of TOP-like motifs</title><p>A) Human CD8<sup>+</sup> Teff cells expressing indicated full-length 3’UTR fused to a GFP reporter, or GFP empty control (<italic>GFP-Control</italic>) were activated for indicated time points with PMA/Ionomycin in the presence of 250nM Torin-1 (red) or 0.05% DMSO control (blue). Top panel: Representative GFP expression at 12h post activation as determined by flow cytometry. Bottom panel: Compiled GFP geoMFI from two independently performed experiments. (-) indicates non-activated T cells treated with Torin-1 or DMSO for 12h. (n=3-6 donors, mean ± SD)</p><p>B) Teff cells expressing GFP with indicated WT cytokine 3’UTRs or CTTT mutant variants thereof (CTTTàCTGT) were activated with PMA/Ionomycin in the presence of Torin-1 or DMSO. Each GFP geoMFI expression was normalized to its paired DMSO control. (n=3 donors, mean ± SD).</p><p>C) -E) Teffs were transduced with full length <italic>TNF</italic> (C), <italic>IL2</italic> (D) and <italic>IFNG</italic> (E) 3’UTRs, or with indicated fragments (fragments containing CTTT motifs indicated) and activated with PMA/Ionomycin in the presence of Torin-1 or DMSO. GFP <italic>Control</italic> and <italic>GZMB</italic> served as control. Heatmap scale representative of GFP ratio between DMSO/Torin-1 treated cells. (n=3 donors). A-C: One sided paired student t test; *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001.</p><p>Also see <xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 1, 2</xref>.</p></caption><graphic xlink:href="EMS199179-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>mTOR promotes 3’UTR-mediated protein expression through AU-rich elements</title><p>A) -C) CD8<sup>+</sup> Teff cells expressing indicated full-length <italic>TNF</italic> (A), <italic>IL2</italic> (B) and <italic>IFNG</italic> (C) 3’UTRs or the respective CTTT mutants (CTTT -&gt; CGTT) or ARE mutants (TATTTA -&gt; TATGTA), <italic>Control</italic> or <italic>GZMB</italic> 3’UTR GFP controls were activated with PMA/Ionomycin in the presence of Torin-1 (red) or DMSO (blue). Left: Representative GFP expression at 12h post activation. Right: Heatmap depicting the GFP ratio between DMSO/Torin-1 treated cells. (n=3 donors). (-) indicates non-activated T cells that were treated with Torin-1 or DMSO for 12h. Data of WT cytokine 3’UTR were also included in <xref ref-type="fig" rid="F1">Figure 1A</xref>. One sided paired student t test; *p &lt; 0.05, **p &lt; 0.01, ****p &lt; 0.0001.</p></caption><graphic xlink:href="EMS199179-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Identification of mTOR-regulated RBPs that interact with the <italic>IL2</italic> 3’UTR</title><p>A) Scheme of <italic>IL2</italic> 3’UTR aptamer pulldown to identify mTOR driven ARE binding proteins using <italic>in vitro</italic> transcribed RNA. CD3<sup>+</sup> Teff cells generated from 40 pooled donors (n=3 donor pools) were activated with αCD3/αCD28 for 3h in the presence of Torin-1 or DMSO. Cell lysates were incubated with <italic>in vitro</italic> transcribed 4xS1m RNA aptamers containing the full length <italic>IL2</italic> WT or <italic>IL2</italic> ARE-mut 3’UTR. Protein binding to 4xS1m RNA aptamers was identified by label-free MS analysis.</p><p>B) Volcano plot of proteins identified in <italic>IL2</italic> WT or <italic>IL2</italic> ARE-mut in DMSO conditions. Only proteins identified in all three replicates were considered putative ARE binders. Red dots represent proteins that were significantly enriched in the presence of the <italic>IL2</italic> WT 3’UTR; blue dots represent proteins enriched in <italic>IL2</italic> ARE-mut 3’UTR.</p><p>C) LFQ intensities of top ARE-binding hits from (B) shown in <italic>IL2</italic> WT 3’UTR (green) or <italic>IL2</italic> ARE-mut 3’UTR (blue) in Torin-1 and DMSO conditions. (n=3 donor pools)</p><p>D) Heatmap of supervised classification displaying proteins that were enriched in <italic>IL2</italic> WT 3’UTR under DMSO conditions (ARE-BP Torin repelled), or proteins enriched in <italic>IL2</italic> WT 3’UTR under Torin-1 conditions, (ARE-BP Torin-1 induced). Correlation between hits and disorder specific theoretical protein profiles had a pearson correlation of &gt;0.75.</p><p>E) LFQ intensities of identified ARE-BPs that were ARE-BP Torin repelled or ARE-BP Torin-1 induced in (D). Top: Aptamer Pulldown Below: Total Cell Lysate. (n= 3 donor pools). Two-sided t test; FDR = 0.05, S0 = 0.4. na: not applicable.</p><p>Also see <xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 3</xref> and <xref ref-type="supplementary-material" rid="SD2">Supplemental Tables 1</xref>, <xref ref-type="supplementary-material" rid="SD3">2</xref>, <xref ref-type="supplementary-material" rid="SD4">3</xref>.</p></caption><graphic xlink:href="EMS199179-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>mTOR promotes protein expression through the 3’UTR-binding protein DDX21</title><p>A) Immunoblot of CD3<sup>+</sup> Teff cells 6 days after CRISPR-Cas9 gene editing for indicated RBP, or with non-targeting crRNA (ctrl).</p><p>B) –D) RBP knockout or non-targeting crRNA (Ctrl) CD3<sup>+</sup> Teff cells expressing <italic>GFP-IL2</italic> 3’UTR were activated with PMA/Ionomycin. (B) Representative histogram of GFP expression at 12h post activation. geoMFI indicated for each sample at the right. (C) geoMFI of Torin-1 (red) or DMSO (blue) treated cells. (-) indicates non-activated T cells treated with Torin-1 or DMSO for 12h. (n=3-6 donors, mean ± SD). (D) Corresponding Forest plot with Bayesian parameter estimates for the mean DMSO/Torin-1 fraction differences between RBP KO cells calculated with 95% credible intervals.</p><p>E) -F) CD8<sup>+</sup> Teff cells expressing <italic>GFP</italic>-<italic>IL2</italic> 3’UTR or <italic>GFP-IL2</italic> ARE-mut 3’UTR and gene-edited for DDX21 knockout or non-targeting crRNA (Ctrl) were activated with PMA/Ionomycin in the presence of Torin-1 or DMSO. (E) geoMFI of GFP plotted for time points. (F) Heatmap scale representative of GFP ratio between DMSO/Torin-1 treated cells. GFP <italic>control</italic> and <italic>GZMB</italic>-3’UTR served as control. (n=2-4 donors, mean ± SD, compiled from 2 independently performed experiments)</p><p>G) Log2 intensity levels of DDX21 protein binding to the full length 3’UTRs of human <italic>TNF, IL2, IFNG</italic> relative to <italic>Empty Vector (EV)</italic> control in CD3<sup>+</sup> Teff cells that were activated for 2h with PMA/Ionomycin. (n=3 donor pools). Data extracted from Popovic <italic>et al.</italic> <sup><xref ref-type="bibr" rid="R31">31</xref></sup> E-G: One sided paired student t test; *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001.</p><p>Also see <xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 4</xref>.</p></caption><graphic xlink:href="EMS199179-f004"/></fig></floats-group></article>